TY - JOUR
T1 - Discriminative ability of quality of life measures in multiple sclerosis
AU - Fiest, Kirsten M.
AU - Greenfield, Jamie
AU - Metz, Luanne M.
AU - Patten, Scott B.
AU - Jetté, Nathalie
AU - Marrie, Ruth Ann
N1 - Funding Information:
K. Fiest has received research funding from the Department of Critical Care Medicine, O’Brien Institute for Public Health and Calgary Centre for Clinical Research, all University of Calgary and the Critical Care Strategic Clinical Network, Alberta Health Services. S. Patten is the recipient of a salary support award (Senior Health Scholar) from Alberta Innovates, Health Solutions and receives research funding from CIHR, the Institute of Health Economics and the Alberta Collaborative Research Grants Initiative. N. Jette is the holder of a Canada Research Chair in Neurological Health Services Research and received funding from: CIHR, Alberta Health, the Hotchkiss Brain Institute and the University of Calgary Cumming School of Medicine. R. A. Marrie receives research funding from: CIHR, Public Health Agency of Canada, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Rx & D Health Research Foundation, National Multiple Sclerosis Society, Crohn’s and Colitis Canada, the Consortium of MS Centers, the Waugh Family Chair in Multiple Sclerosis.
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/12/21
Y1 - 2017/12/21
N2 - Background: Though many people with multiple sclerosis (MS) have comorbidities, the use of generic and disease-specific health related quality of life (HRQOL) scales to discriminate the effects of comorbidity has not been established. The utility of these scales to discriminate differences between persons with varying levels of disability is also unknown. Methods: Using online questionnaires, a convenience sample of Albertans with MS was recruited between July 2011 and March 2013. Participants completed demographic questions, a validated comorbidity questionnaire, a self-reported disability scale, and the following HRQOL scales: the Short Form (SF)-36, SF-6D, Health Utilities Index-Mark III (HUI-III), and Multiple Sclerosis Quality of Life-54 (MSQOL-54). The ability of each HRQOL scale to distinguish between comorbidity groups was assessed using a one-way analysis of covariance, adjusting for age, sex, disease course, and disability level. Results: Five hundred sixty three participants completed all relevant questionnaires. All HRQOL measures distinguished between persons with or without depression, while none were able to distinguish between participants with or without hypertension, thyroid disease, irritable bowel syndrome, or osteoporosis. The SF-36 physical scale, SF-6D, HUI-III, and MSQOL-54 physical scales were able to distinguish between all disability groups, though the HUI-III was better able to distinguish between individuals with moderate versus severe disability. Conclusions: Disease-specific measures would discriminate better between those with and without comorbidities than generic-specific measures and the HUI-III would discriminate best between persons with differing severities of disability. Generic or disease-specific measures may be useful in future studies examining the effects of comorbidity in MS and the effects of treatment of comorbidities in MS.
AB - Background: Though many people with multiple sclerosis (MS) have comorbidities, the use of generic and disease-specific health related quality of life (HRQOL) scales to discriminate the effects of comorbidity has not been established. The utility of these scales to discriminate differences between persons with varying levels of disability is also unknown. Methods: Using online questionnaires, a convenience sample of Albertans with MS was recruited between July 2011 and March 2013. Participants completed demographic questions, a validated comorbidity questionnaire, a self-reported disability scale, and the following HRQOL scales: the Short Form (SF)-36, SF-6D, Health Utilities Index-Mark III (HUI-III), and Multiple Sclerosis Quality of Life-54 (MSQOL-54). The ability of each HRQOL scale to distinguish between comorbidity groups was assessed using a one-way analysis of covariance, adjusting for age, sex, disease course, and disability level. Results: Five hundred sixty three participants completed all relevant questionnaires. All HRQOL measures distinguished between persons with or without depression, while none were able to distinguish between participants with or without hypertension, thyroid disease, irritable bowel syndrome, or osteoporosis. The SF-36 physical scale, SF-6D, HUI-III, and MSQOL-54 physical scales were able to distinguish between all disability groups, though the HUI-III was better able to distinguish between individuals with moderate versus severe disability. Conclusions: Disease-specific measures would discriminate better between those with and without comorbidities than generic-specific measures and the HUI-III would discriminate best between persons with differing severities of disability. Generic or disease-specific measures may be useful in future studies examining the effects of comorbidity in MS and the effects of treatment of comorbidities in MS.
KW - Comorbidity
KW - Concordance
KW - Health utility
KW - Multiple sclerosis
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85038965523&partnerID=8YFLogxK
U2 - 10.1186/s12955-017-0828-0
DO - 10.1186/s12955-017-0828-0
M3 - Article
C2 - 29268750
AN - SCOPUS:85038965523
SN - 1477-7525
VL - 15
JO - Health and Quality of Life Outcomes
JF - Health and Quality of Life Outcomes
IS - 1
M1 - 246
ER -